

## 4Moving Biotech announces an equity investment by the Arthritis Foundation to support the clinical development of its osteoarthritis drug candidate

**Lille, France, November 17th, 2022 – 4Moving Biotech**, a subsidiary of 4P-Pharma, specializing in the development of a disease-modifying osteoarthritis drug (DMOAD) for osteoarthritis, announces a strategic alliance with the Arthritis Foundation by acquiring an equity stake in the company and supporting the clinical development of its osteoarthritis drug candidate.

### About the Strategic Alliance

The research work of Prof. Francis Berenbaum has made it possible to identify a new class of molecules against osteoarthritis. In particular, 4P004, co-developed by 4P-Pharma and brought to the clinical stage by 4Moving Biotech, combines anti-inflammatory, anti-catabolic and pro-anabolic properties, and its clinical potential is aimed at both improving the quality of life of patients and slowing down the progression of the disease.

Historically associated with Prof. Berenbaum's work through research grants, and in its ambition to be able to offer an effective therapeutic solution to patients suffering from osteoarthritis, the Arthritis Foundation is pursuing its commitment through support for the clinical program as well as an investment in the capital of 4Moving Biotech, which will benefit from the institutional anchoring of the foundation with researchers, physicians and patient associations.

"We are very pleased with the commitment of the Foundation Arthritis. Patients have always been at the heart of our research": said Prof. Francis Berenbaum, *co-founder and CEO/CMO of 4Moving Biotech, Professor at Sorbonne University and head of the rheumatology department at St-Antoine Hospital (AP-HP) in Paris*. "The support of a public utility foundation such as the Arthritis Foundation is the recognition of the quality of our scientific studies to bring innovative treatments to osteoarthritis patients around the world."

"Arthritis Foundation has unveiled its "ambition 2030", which is focused on patient impact and associated with a scientific strategy of funding excellence. I am pleased to give concrete expression to this desire by diversifying our commitments so that the research continuum between a researcher's idea, his fundamental research and translation to the clinical phases is assured. 4moving Biotech gives meaning to this new 2030 ambition." Lionel Comole, *Executive Director of the Arthritis Foundation*.

### About osteoarthritis

Osteoarthritis is a chronic destructive disease of the joints. It is the leading cause of disability in people over the age of 50. Worldwide, more than 300 million people are affected, representing 15% of the adult population. Nearly one in two adults will develop osteoarthritis of the knee or hip in their lifetime. Due to the aging of the population and the increase in obesity rates, the prevalence of this painful and disabling disease is rising sharply. In France, more than 8.4 million people live with this disease.

## Press release

Lille, November 17th, 2022

### About 4Moving Biotech

4Moving Biotech is a biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD) candidate 4P004. Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis.

4Moving Biotech was founded in July 2020 and is a majority-owned subsidiary of 4P-Pharma. The company is headquartered at the Pasteur Institute in Lille, France.

Site internet : <https://www.4movingbiotech.com/>

LinkedIn: <https://fr.linkedin.com/company/4moving-biotech>

Twitter: [https://twitter.com/4Moving\\_Biotech](https://twitter.com/4Moving_Biotech)

### About 4P-Pharma

4P-Pharma is a biotech company focused on active drug regeneration with the goal of developing curative treatments for serious diseases that are currently incurable.

Driven by the vision of linking the pathophysiology of diseases with unmet needs to the mechanisms of drug action, 4P-Pharma is distinguished by the dual leverage of its internal R&D capabilities combined with the creation of a company Single Product Vehicle (SPV) with a vocation to pursue the clinical stage development of drug candidates.

Site internet : <https://4p-pharma.com/fr>

LinkedIn: <https://fr.linkedin.com/company/4p-pharma>

Twitter: [https://twitter.com/4p\\_pharma](https://twitter.com/4p_pharma)

### About the Arthritis Fondation

The Arthritis foundation is the leading private initiative in France to fund research on RMS. Its missions are prevention, awareness, communication and funding of medical research in the field of RMS.

The Foundation supports all aspects of research. It makes a special effort to promote so-called "translational" research.

This research aims to accelerate the transition from fundamental data to clinical proof. In this respect, the Arthritis Fondation proposes to help mixed teams of researchers and clinicians to promote innovative projects, both to develop new diagnostic tools and to discover new treatments for severe rheumatism. The clinical aspect of research, which is done in direct contact with patients and their families, is also supported by encouraging the development of epidemiological studies or innovative clinical trials.

Site internet : <https://fondation-arthritis.org>

LinkedIn: <https://www.linkedin.com/company/fondationarthritis/>

### **Contact press - 4P-Pharma et 4Moving Biotech**

**Emmanuelle Lopez** - CFO

Email : [Emmanuelle.lopez@4p-pharma.com](mailto:Emmanuelle.lopez@4p-pharma.com)

**Emmanuel Dadjé** – Communication Service

E-mail : [emmanuel.dadje@4p-pharma.com](mailto:emmanuel.dadje@4p-pharma.com)

Office : + 33 1 44 97 40 59